4.6 Article

Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α

Journal

NEURO-ONCOLOGY
Volume 17, Issue 6, Pages 832-842

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nou323

Keywords

Dock180; glioblastomas; PDGFR alpha; phosphorylation; PKA

Funding

  1. NIH [CA130966, CA158911, NS080619, CA159467]
  2. Zell Scholar Award from the Zell Family Foundation
  3. Northwestern Brain Tumor Institute
  4. Department of Neurology at Northwestern University Feinberg School of Medicine
  5. Brain Cancer Research Award from the James S. McDonnell Foundation
  6. National Natural Science Foundation of China [81372704, 81470315, 81330015, 81130038, 81372189]
  7. Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission [14ZZ111]
  8. State Key Laboratory of Oncogenes and Related Genes in China [90-14-04]
  9. Pujiang Talent Plan of Shanghai City, China [14PJ1406500]
  10. Natural Science Foundation of Tianjin City, China [13JCYBJC39400]
  11. Chinese Ministry of Science and Technology [2012CB966800]
  12. Key Discipline and Specialty Foundation of Shanghai Health Bureau
  13. KC Wong Foundation
  14. Mayo Brain Tumor SPORE [CA108961]
  15. Mayo Clinic
  16. Michael J. Marchese Endowed Chair in Neurological Surgery at Northwestern University

Ask authors/readers for more resources

Background. Dedicator of cytokinesis 1 (Dock1 or Dock180), a bipartite guanine nucleotide exchange factor for Rac1, plays critical roles in receptor tyrosine kinase-stimulated cancer growth and invasion. Dock180 activity is required in cell migration cancer tumorigenesis promoted by platelet derived growth factor receptor (PDGFR) and epidermal growth factor receptor. Methods. To demonstrate whether PDGFR alpha promotes tumor malignant behavior through protein kinase A (PKA)-dependent serine phosphorylation of Dock180, we performed cell proliferation, viability, migration, immunoprecipitation, immunoblotting, colony formation, and in vivo tumorigenesis assays using established and short-term explant cultures of glioblastoma cell lines. Results. Stimulation of PDGFR alpha results in phosphorylation of Dock180 at serine residue 1250 (S1250), whereas PKA inhibitors H-89 and KT5720 oppose this phosphorylation. S1250 locates within the Rac1-binding Dock homology region 2 domain of Dock180, and its phosphorylation activates Rac1, p-Akt, and phosphorylated extracellular signal-regulated kinase 1/2, while promoting cell migration, in vitro. By expressing RNA interference (RNAi)-resistant wild-type Dock180, but not mutant Dock180 S1250L, we were able to rescue PDGFR alpha-associated signaling and biological activities in cultured glioblastoma multiforme (GBM) cells that had been treated with RNAi for suppression of endogenous Dock180. In addition, expression of the same RNAi-resistant Dock180 rescued an invasive phenotype of GBM cells following intracranial engraftment in immunocompromised mice. Conclusion. These data describe an important mechanism by which PDGFR alpha promotes glioma malignant phenotypes through PKA-dependent serine phosphorylation of Dock180, and the data thereby support targeting the PDGFR alpha-PKA-Dock180-Rac1 axis for treating GBM with molecular profiles indicating PDGFR alpha signaling dependency.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Oncology

New life for an old therapy: ELTD1 as a downstream target of angiogenesis

Deanna Marie Tiek, Shi-Yuan Cheng

NEURO-ONCOLOGY (2022)

Correction Chemistry, Multidisciplinary

KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (vol 8, 2100014, 2021)

Bo Yu, Fei Luo, Bowen Sun, Wenxue Liu, Qiqi Shi, Shi-Yuan Cheng, Ceshi Chen, Guoqiang Chen, Yanxin Li, Haizhong Feng

ADVANCED SCIENCE (2022)

Article Cell & Tissue Engineering

Optimizing the Method for Differentiation of Macrophages from Human Induced Pluripotent Stem Cells

Shanshan Li, Lili Song, Yingwen Zhang, Zhiyan Zhan, Yi Yang, Lisha Yu, Hua Zhu, Weihua Huang, Wanqiao Wang, Haizhong Feng, Yanxin Li

Summary: This study describes a reliable method to produce functional macrophages through the differentiation of human induced pluripotent stem cells (hiPSCs). By optimizing the size control of embryoid bodies (EBs), the differentiation process of macrophages was accelerated and the production increased without attenuating macrophage functions. The final yield of macrophages was close to 50-fold of starting iPSCs, and the macrophages showed phagocytic capacity in vitro and in a xenograft tumor model.

STEM CELLS INTERNATIONAL (2022)

Editorial Material Oncology

Targeting neddylation in cancer

Anshika Goenka, Shi-Yuan Cheng

NEURO-ONCOLOGY (2022)

Article Oncology

Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts

Matthew McCord, Elizabeth Bartom, Kirsten Burdett, Aneta Baran, Frank D. Eckerdt, Irina Balyasnikova, Kathleen McCortney, Thomas Sears, Shi-Yuan Cheng, Jann N. Sarkaria, Roger Stupp, Amy B. Heimberger, Atique Ahmed, Charles David James, Craig Horbinski

Summary: This study developed therapy-resistant glioblastoma patient-derived xenografts (PDX) by exposing them to radiation and temozolomide. These PDX models reflect key features of recurrent glioblastoma and can serve as valuable tools for testing new therapies.

CANCERS (2022)

Article Oncology

The mammalian Sterile 20-like kinase 4 (MST4) signaling in tumor progression: Implications for therapy

Ayechew A. Getu, Ming Zhou, Shi-Yuan Cheng, Ming Tan

Summary: Cancer, a complex and dynamic disease, remains a leading cause of death in humans. The Mammalian Sterile 20-Like Kinase 4 (MST4 or STK26) plays a crucial role in cell migration and polarity, and is involved in various processes such as tumor cell proliferation, migration, invasion, survival, and cancer metastasis. MST4 interacts with PDCD10 to promote tumor growth and migration, and phosphorylates ATG4B to mediate autophagy signaling and contribute to treatment resistance. Overall, MST4 functions as an oncogene and shows potential as a therapeutic target.

CANCER LETTERS (2023)

Article Oncology

Oncogenic long noncoding RNA LINC02283 enhances PDGF receptor A-mediated signaling and drives glioblastoma tumorigenesis

Anshika Goenka, Xiao Song, Deanna Tiek, Rebeca Piatniczka Iglesia, Minghui Lu, Chang Zeng, Craig Horbinski, Wei Zhang, Bo Hu, Shi-Yuan Cheng

Summary: In this study, a novel oncogenic long noncoding RNA (lncRNA) called LINC02283 was identified. It is highly expressed in glioma patients with PDGFRA mutation and is associated with poor prognosis. LINC02283 interacts with PDGFRA to enhance its signaling pathway and promote oncogenesis in glioblastoma. These findings provide strong evidence for the potential of lncRNAs as therapeutic targets.

NEURO-ONCOLOGY (2023)

Article Oncology

Repurposing Clemastine to Target Glioblastoma Cell Stemness

Michael A. Sun, Rui Yang, Heng Liu, Wenzhe Wang, Xiao Song, Bo Hu, Nathan Reynolds, Kristen Roso, Lee H. Chen, Paula K. Greer, Stephen T. Keir, Roger E. McLendon, Shi-Yuan Cheng, Darell D. Bigner, David M. Ashley, Christopher J. Pirozzi, Yiping He

Summary: In this study, researchers discovered that clemastine, a non-oncology drug for allergy relief, can inhibit the proliferation and promote differentiation of brain tumor-initiating cells (BTICs). They also identified the essential role of Emopamil-binding protein (EBP) in maintaining the BTIC population. These findings provide valuable insights for developing new treatments for glioblastoma.

CANCERS (2023)

Meeting Abstract Oncology

REPURPOSING CLEMASTINE TO SUPPRESS GLIOBLASTOMA STEM CELLS

Michael Sun, Rui Yang, Heng Liu, Wenzhe Wang, Xiao Song, Bo Hu, Nathan Reynolds, Kristen Roso, Lee Chen, Paula Greer, Shi-Yuan Cheng, David Ashley, Christopher Pirozzi, Yiping He

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

TEMOZOLOMIDE-INDUCED GUANINE MUTATIONS CREATE EXPLOITABLE VULNERABILITIES OF GUANINE-RICH DNA AND RNA REGIONS IN DRUG-RESISTANT GLIOMAS

Deanna Tiek, Shi-Yuan Cheng, Xiao Song, Anshika Goenka, Rebeca Iglesia, Bo Hu, Rebecca Riggins

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

THE PDGFRA-REGULATING LNCRNA LINC02283 IS AMPLIFIED IN HIGH-GRADE GLIOMA AND FACILITATES GLIOMAGENESIS

Anshika Goenka, Xiao Song, Deanna Tiek, Bo Hu, Shi-Yuan Cheng

NEURO-ONCOLOGY (2022)

Meeting Abstract Clinical Neurology

Temozolomide-Induced Guanine Mutations Create Exploitable Vulnerabilities of Guanine-Rich DNA and RNA Regions in Drug Resistant Gliomas

Deanna Tiek, Xiao Song, Anshika Goenka, Rebeca Iglesia, Bo Hu, Rebecca Riggins, Shi-Yuan Cheng

ANNALS OF NEUROLOGY (2022)

Meeting Abstract Clinical Neurology

Subtype-Associated RNA Splicing Controlled by Glioma Driver Mutations Regulates Gliomagenesis

Xiao Song, Tianzhi Huang, Deanna Tiek, Shunichiro Miki, Anshika Goenka, Rebeca Iglesia, Frank B. Furnari, Bo Hu, Shi-Yuan Cheng

ANNALS OF NEUROLOGY (2022)

Meeting Abstract Clinical Neurology

Oncogenic Long Non-Coding RNA LINC02283 Enhances PDGF Receptor A Mediated Signaling and Drives Glioblastoma Tumorigenesis

Anshika Goenka, Xiao Song, Deanna M. Tiek, Bo Hu, Shi-Yuan Cheng

ANNALS OF NEUROLOGY (2022)

Review Oncology

DNA damage and metabolic mechanisms of cancer drug resistance

Deanna Tiek, Shi-Yuan Cheng

Summary: This review discusses different strategies to combat cancer drug resistance, including synthetic lethality and modulation of the tumor microenvironment. By understanding the relationship between targetable mutations and metabolism in tumor cells and their surrounding microenvironment, smarter drugs can be designed to fight cancer drug resistance.

CANCER DRUG RESISTANCE (2022)

No Data Available